EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

BACKGROUND: Lung adenocarcinoma with EGFR activating mutations will inevitably acquire resistance to first generation TKIs. Acquired EGFR T790M mutation causes about 50% of these resistance cases. Droplet digital PCR (ddPCR) and cobas enables quantification of T790M mutation. Whether these methods c...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chenguang, Jia, Rui, Liu, Hailin, Zhang, Bin, Wang, Changli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090640/
https://www.ncbi.nlm.nih.gov/pubmed/30103780
http://dx.doi.org/10.1186/s13000-018-0728-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090640/
https://www.ncbi.nlm.nih.gov/pubmed/30103780
http://dx.doi.org/10.1186/s13000-018-0728-6

Ejemplares similares